The Growth/Differentiation Factor-15 in Chronic Heart Failure: New Challenge in Biomarker-Guided Therapy?

Abstract

Heart failure (HF) biomarker-guided therapy is promising method, which directs to improving of clinical status, attenuation of admission/readmission to the hospital and reduces of mortality rate. Many biological markers, i.e. inflammatory cytokines, are under consideration as a surrogate target for HF treatment, while there is known biomarkers with established predictive value, such as natriuretic peptides. However, discovery of new biomarkers reflecting various underlying mechanisms of HF and appearing to be surrogate targets for biomarkerguided therapy is promising. Nowadays, growth differentiation factor 15 (GDF-15) is suggested a target biomarker for HF treatment. Although elevated level of GDF-15 associated with HF development, progression, and prognosis, there is not represented evidence regarding direct comparison of this biomarker with other clinical risk predictors and biomarkers. Moreover, GDF-15 might serve as a contributor to endothelial progenitor cells (EPC) dysfunction by inducing EPC death/autophagy and limiting their response to angiopoetic and reparative effects. The short communication is discussed whether GDF-15 is good molecular target for HF guided therapy.

Czynnik różnicowania wzrostu 15 jako biomarker w niewydolności serca

“…Nie jest też jasne, czy w toku skutecznego leczenia jego stężenia zachowywałyby się podobnie do wartości BNP [28]. U pacjentów z HF leczonych walsartanem stężenie GDF-15 po 12 miesiącach leczenia było wyższe niż wyjściowe, natomiast stężenie BNP obniżyło się [29].…”